Atherosclerosis is the pathological basis of cardiovascular disease, whilst endothelial dysfunction (ED) plays a primary role in the occurrence and development of atherosclerosis. Simvastatin has been shown to possess significant anti-atherosclerosis activity. In this study, we evaluated the protective effect of simvastatin on endothelial cells under oxidative stress and elucidated its underlying mechanisms. Simvastatin was found to attenuate H 2 O 2 -induced human umbilical vein endothelial cells (HUVECs) dysfunction and inhibit the Wnt/β-catenin pathway; however, when this pathway was activated by lithium chloride, endothelial dysfunction was clearly enhanced. Further investigation revealed that simvastatin did not alter the expression or phosphorylation of LRP6, but reduced intracellular cholesterol deposition and inhibited endoplasmic reticulum (ER) stress. Inducing ER stress with tunicamycin activated the Wnt/β-catenin pathway, whereas reducing ER stress with 4-phenylbutyric acid inhibited it. We hypothesize that simvastatin does not affect transmembrane signal transduction in the Wnt/β-catenin pathway, but inhibits ER stress by reducing intracellular cholesterol accumulation, which blocks intracellular signal transduction in the Wnt/β-catenin pathway and ameliorates endothelial dysfunction.
Introduction
Globally, the incidence and mortality rates of cardiovascular diseases remain very high [1] . Atherosclerosis (AS) is an important contributor towards the development cardiovascular and cerebrovascular diseases, whilst endothelial cell (EC) dysfunction plays a crucial role in the development of AS, since the overexpression of adhesion molecules and the release of inflammatory factors promote the formation of foam cells from macrophages [2] . Many studies have shown that oxidative stress is an important factor in EC dysfunction, as reactive oxygen species are small signaling molecules that play important roles in the regulation of biological processes and cellular functions [3] . When intracellular reactive oxygen species levels exceed the cell tolerance limit, the excess reactive oxygen species attack the mitochondrial membrane, leading to mitochondrial dysfunction and EC dysfunction [4, 5] . Therefore, the mechanisms of oxidative stress-induced EC dysfunction urgently require further study. 
Simvastatin Attenuates Oxidative Stress-Induced Endothelial Cell Dysfunction by Inhibiting the Wnt/β-Catenin Pathway
To evaluate the protective effect of simvastatin on HUVECs under oxidative stress, cell viability and the expression of Bax and Bcl-2 were measured. In the Li group, cell viability and Bcl-2 expression were 35% and 37% lower than that in the C group, respectively (Figure 2a) , whilst in the Sim group, they were 32% and 34% higher than that in the C group, respectively. As expected, cell viability and Bcl-2 expression were lower in the Li+Sim group than in the Sim group (Figure 2a 
To evaluate the protective effect of simvastatin on HUVECs under oxidative stress, cell viability and the expression of Bax and Bcl-2 were measured. In the Li group, cell viability and Bcl-2 expression were 35% and 37% lower than that in the C group, respectively (Figure 2a) , whilst in the Sim group, they were 32% and 34% higher than that in the C group, respectively. As expected, cell viability and Bcl-2 expression were lower in the Li+Sim group than in the Sim group (Figure 2a , p < 0.05, n = 3 or 6) but higher than in the Li group (Figure 2b , p < 0.001, n = 3 or 6), whilst the opposite result was observed for Bax expression (Figure 2b , p < 0.001, n = 3).
LDH levels in the medium and intracellular MDA concentration and SOD activity were also determined. LDH levels and MDA concentration were 23% and 35% higher in the Li group, and 20% and 38% lower in the Sim group than in the C group, respectively. LDH levels and MDA concentration in the Li+Sim group were lower than those in the Li group (Figure 2c , p < 0.05, n = 3) but higher than those in the Sim group (Figure 2d , p < 0.001, n = 3). SOD activity was 43% lower in the Li group and 53% higher in the Sim group than in the C group (Figure 2e, p < 0.001, n = 3), and was higher in the Li+Sim group than in the Li group, but lower in the Li+Sim group than in the Sim group (Figure 2e , p < 0.001, n = 3). LDH levels in the medium and intracellular MDA concentration and SOD activity were also determined. LDH levels and MDA concentration were 23% and 35% higher in the Li group, and 20% and 38% lower in the Sim group than in the C group, respectively. LDH levels and MDA concentration in the Li+Sim group were lower than those in the Li group (Figure 2c , p < 0.05, n = 3) but higher than those in the Sim group (Figure 2d , p < 0.001, n = 3). SOD activity was 43% lower in the Li group and 53% higher in the Sim group than in the C group (Figure 2e , p < 0.001, n = 3), and was higher in the Li+Sim group than in the Li group, but lower in the Li+Sim group than in the Sim group (Figure 2e , p < 0.001, n = 3). 
Simvastatin Reduces Endothelial Cell Adhesion by Inhibiting the Wnt/β-Catenin Pathway

The ability of the HUVECs to adhere to THP-1 cells was assessed by counting the number of THP-1 cells adhered to the HUVECs. As shown in Figure 3a , the number of THP-1 cells adhered to HUVECs in the Sim group was 16% lower than that in the C group (p < 0.001, n = 3). When the Wnt/β-catenin pathway was activated by LiCl, the adhesion ability of HUVECs increased by 48% (Figure 3a , p < 0.001, n = 3), and was higher in the Li+Sim group than in the Sim group yet lower than in the Li group (Figure 3a , p < 0.05 or 0.001, n = 3). The levels of adhesion molecule expression can affect the adhesion ability of HUVECs. As shown in Figure 3b , VCAM-1, ICAM-1, and MCP-1 expression was 24%, 31%, and 20% lower in the Sim group (p < 0.05, n = 3) and 25%, 44%, and 38% higher in the Li group (p < 0.05, n = 3) than in the C group, respectively. In the Li+Sim group, the expression of all of the adhesion molecules was lower and higher than that in the Li and Sim groups, respectively (Figure 3b , p < 0.05, n = 3). Taken together, these results indicate that simvastatin reduced the adhesion ability of HUVECs by inhibiting the Wnt/β-catenin pathway.
HUVECs in the Sim group was 16% lower than that in the C group (p < 0.001, n = 3). When the Wnt/β-catenin pathway was activated by LiCl, the adhesion ability of HUVECs increased by 48% (Figure 3a , p < 0.001, n = 3), and was higher in the Li+Sim group than in the Sim group yet lower than in the Li group (Figure 3a , p < 0.05 or 0.001, n = 3). The levels of adhesion molecule expression can affect the adhesion ability of HUVECs. As shown in Figure 3b , VCAM-1, ICAM-1, and MCP-1 expression was 24%, 31%, and 20% lower in the Sim group (p < 0.05, n = 3) and 25%, 44%, and 38% higher in the Li group (p < 0.05, n = 3) than in the C group, respectively. In the Li+Sim group, the expression of all of the adhesion molecules was lower and higher than that in the Li and Sim groups, respectively ( Figure  3b , p < 0.05, n = 3). Taken together, these results indicate that simvastatin reduced the adhesion ability of HUVECs by inhibiting the Wnt/β-catenin pathway.
Simvastatin Inhibits ER Stress via the Wnt/β-Catenin Pathway
Under oxidative stress, simvastatin can reduce the injury and adhesion of HUVECs. To investigate the possible underlying mechanisms, the levels of β-catenin and phosphorylated β-catenin were determined by western blotting analysis (Figure 4a , p < 0.05 or 0.001, n = 3). β-catenin protein expression was 34% higher and 20% lower in the Li and Sim groups, respectively, compared to that in the C group. In addition, phospho-β-catenin levels 30% lower and 16% higher in the Li and Sim groups, respectively, compared to that in the C group. The levels of phosphorylated β-catenin in the Li+Sim group were lower than those in the Sim group but higher than those in the Li group. LDL receptor-related protein 6 (LRP6) is a coreceptor of the Wnt/β-catenin pathway, and its phosphorylation activates the downstream Wnt/β-catenin pathway [27] . Lipid rafts can affect transmembrane signaling transduction in the Wnt/β-catenin signaling pathway. To determine whether simvastatin inhibits the Wnt/β-catenin pathway via lipid rafts, western blotting was performed to measure the levels of LRP6 and phosphorylated LRP6. As shown in Figure 4b , their levels in the Li and Sim groups did not significantly differ from those in the control group (p > 0.05, 
Under oxidative stress, simvastatin can reduce the injury and adhesion of HUVECs. To investigate the possible underlying mechanisms, the levels of β-catenin and phosphorylated β-catenin were determined by western blotting analysis ( Figure 4a , p < 0.05 or 0.001, n = 3). β-catenin protein expression was 34% higher and 20% lower in the Li and Sim groups, respectively, compared to that in the C group. In addition, phospho-β-catenin levels 30% lower and 16% higher in the Li and Sim groups, respectively, compared to that in the C group. The levels of phosphorylated β-catenin in the Li+Sim group were lower than those in the Sim group but higher than those in the Li group. different from those in either the Li or Sim groups (Figure 4b , p > 0.05, n = 3). GRP78, ATF6, and CHOP are three key molecules in ER stress. In the Li group, GRP78, ATF6, and CHOP expression was increased by 29%, 61%, and 47%, respectively, compared to that in the C group (Figure 4c , p < 0.05 or 0.001, n = 3), indicating that ER stress may be activated by the Wnt/β-catenin pathway. . Simvastatin inhibits ER stress by inhibiting the Wnt/β-catenin pathway. The expressions of (a) β-catenin, phospho-β-catenin (b) LRP6, phospho-LRP6 (c) GRP78, ATF6 and CHOP in protein levels. * p < 0.05 or ** p < 0.001 versus C group; # p < 0.05 or ## p < 0.001 versus Li+Sim group, n = 3. C, HUVECs treated with H2O2; Li, C group treated with LiCl; Sim, C group treated with simvastatin; Li+Sim, C group treated with simvastatin and LiCl.
In addition, GRP78, ATF6, and CHOP expression levels in the Sim group were 27%, 19%, and 24% lower, respectively, than those in the C group (Figure 4c , p < 0.05 or 0.001, n = 3), whilst in the Li+Sim group, their expression was significantly lower than those in the Li group, but higher than Figure 4 . Simvastatin inhibits ER stress by inhibiting the Wnt/β-catenin pathway. The expressions of (a) β-catenin, phospho-β-catenin (b) LRP6, phospho-LRP6 (c) GRP78, ATF6 and CHOP in protein levels. * p < 0.05 or ** p < 0.001 versus C group; # p < 0.05 or ## p < 0.001 versus Li+Sim group, n = 3. C, HUVECs treated with H 2 O 2 ; Li, C group treated with LiCl; Sim, C group treated with simvastatin; Li+Sim, C group treated with simvastatin and LiCl.
LDL receptor-related protein 6 (LRP6) is a coreceptor of the Wnt/β-catenin pathway, and its phosphorylation activates the downstream Wnt/β-catenin pathway [27] . Lipid rafts can affect transmembrane signaling transduction in the Wnt/β-catenin signaling pathway. To determine whether simvastatin inhibits the Wnt/β-catenin pathway via lipid rafts, western blotting was performed to measure the levels of LRP6 and phosphorylated LRP6. As shown in Figure 4b , their levels in the Li and Sim groups did not significantly differ from those in the control group (p > 0.05, n = 3). Likewise, total and phosphorylated LRP6 levels in the Li+Sim group were not significantly different from those in either the Li or Sim groups (Figure 4b , p > 0.05, n = 3).
GRP78, ATF6, and CHOP are three key molecules in ER stress. In the Li group, GRP78, ATF6, and CHOP expression was increased by 29%, 61%, and 47%, respectively, compared to that in the C group (Figure 4c , p < 0.05 or 0.001, n = 3), indicating that ER stress may be activated by the Wnt/β-catenin pathway.
In addition, GRP78, ATF6, and CHOP expression levels in the Sim group were 27%, 19%, and 24% lower, respectively, than those in the C group (Figure 4c , p < 0.05 or 0.001, n = 3), whilst in the Li+Sim group, their expression was significantly lower than those in the Li group, but higher than those in the Sim group (Figure 4c , p < 0.05 or 0.001, n = 3). These results indicate that simvastatin inhibits ER stress and that the Wnt/β-catenin pathway affects ER stress.
Endoplasmic Reticulum Stress Affects the Wnt/β-Catenin Pathway
Tunicamycin is an ER stress activator, whereas 4-PBA is an ER stress inhibitor. As shown in Figure 5a , β-catenin expression increased by 48% and decreased by 20% after tunicamycin and 4-PBA treatment, respectively (p < 0.001, n = 3); however, phosphorylated β-catenin levels decreased by 24% and increased by 30% after tunicamycin and 4-PBA treatment, respectively (p < 0.001, n = 3). GRP78, ATF6, and CHOP expression increased by 58%, 76%, and 42%, respectively, after tunicamycin treatment, but decreased by 42%, 53%, and 26%, respectively, after 4-PBA treatment (Figure 5b , p < 0.001, n = 3). Thus, endoplasmic reticulum stress affects the Wnt/β-catenin pathway. 
Tunicamycin is an ER stress activator, whereas 4-PBA is an ER stress inhibitor. As shown in Figure 5a , β-catenin expression increased by 48% and decreased by 20% after tunicamycin and 4-PBA treatment, respectively (p < 0.001, n = 3); however, phosphorylated β-catenin levels decreased by 24% and increased by 30% after tunicamycin and 4-PBA treatment, respectively (p < 0.001, n = 3). GRP78, ATF6, and CHOP expression increased by 58%, 76%, and 42%, respectively, after tunicamycin treatment, but decreased by 42%, 53%, and 26%, respectively, after 4-PBA treatment (Figure 5b , p < 0.001, n = 3). Thus, endoplasmic reticulum stress affects the Wnt/β-catenin pathway.
Simvastatin Reduces the Deposition of Cholesterol in the Cytoplasm
To explore the possible mechanism underlying the inhibition of ER stress by simvastatin, intracellular cholesterol was measured by Filipin staining, as fluorescence intensity is proportional to intracellular cholesterol content. As shown in Figure 6 , the cholesterol content was 25% higher in the Li group (p < 0.001, n = 3) and 35% lower in the Sim group (p < 0.001, n = 3) than in the C group, whilst it was significantly lower in the Li+Sim group than that in the Li group and higher than that in the Sim group (p < 0.05 or 0.001, n = 3). 
To explore the possible mechanism underlying the inhibition of ER stress by simvastatin, intracellular cholesterol was measured by Filipin staining, as fluorescence intensity is proportional to intracellular cholesterol content. As shown in Figure 6 , the cholesterol content was 25% higher in the Li group (p < 0.001, n = 3) and 35% lower in the Sim group (p < 0.001, n = 3) than in the C group, whilst it was significantly lower in the Li+Sim group than that in the Li group and higher than that in the Sim group (p < 0.05 or 0.001, n = 3). Molecules 2019, 24, x 8 of 14 Figure 6 . Simvastatin reduces the deposition of cholesterol in the cytoplasm. The intracellular cholesterol was measured by Filipin staining. ** p < 0.001 versus C group; # p < 0.05 or ## p < 0.001 versus Li+Sim group, n = 3. C, HUVECs treated with H2O2; Li, C group treated with LiCl; Sim, C group treated with simvastatin; Li+Sim, C group treated with simvastatin and LiCl.
Discussion
Simvastatin treatment reduces the risk of cardiovascular events and cardiovascular diseaserelated deaths, predominantly by decreasing intracellular and circulating cholesterol levels [7] [8] [9] [10] ; however, the role of simvastatin in ECs remains unclear. In this study, we found that low simvastatin doses increased the viability of HUVECs while high doses reduced their viability. Moreover, we found that low-dose simvastatin treatment blocked the Wnt/β-catenin pathway, whereas higher doses re-activated the pathway (Figure 1) . Previous studies have shown that the activation of this pathway induces EC dysfunction [17, 18] . These results suggest that low-dose simvastatin treatment may reduce HUVEC dysfunction by inhibiting the Wnt/β-catenin pathway.
To determine whether simvastatin could reduce Wnt/β-catenin pathway-induced EC dysfunction, LiCl was used to activate this pathway in HUVECs. LiCl inhibited the phosphorylation of cytoplasmic β-catenin, confirming Wnt/β-catenin pathway activation (Figure 4a ). Reduced β-catenin phosphorylation prevents its degradation, leading to cytoplasmic accumulation and translocation into the nucleus. As expected, LiCl increased EC dysfunction (Figures 2 and 3) , further confirming that simvastatin regulates the Wnt/β-catenin pathway; we propose that simvastatin exerts a protective effect by inhibiting the Wnt/β-catenin pathway via β-catenin phosphorylation (Figure 4 ), leading to its degradation and reduced nuclear translocation. 
Simvastatin treatment reduces the risk of cardiovascular events and cardiovascular disease-related deaths, predominantly by decreasing intracellular and circulating cholesterol levels [7] [8] [9] [10] ; however, the role of simvastatin in ECs remains unclear. In this study, we found that low simvastatin doses increased the viability of HUVECs while high doses reduced their viability. Moreover, we found that low-dose simvastatin treatment blocked the Wnt/β-catenin pathway, whereas higher doses re-activated the pathway (Figure 1) . Previous studies have shown that the activation of this pathway induces EC dysfunction [17, 18] . These results suggest that low-dose simvastatin treatment may reduce HUVEC dysfunction by inhibiting the Wnt/β-catenin pathway.
To determine whether simvastatin could reduce Wnt/β-catenin pathway-induced EC dysfunction, LiCl was used to activate this pathway in HUVECs. LiCl inhibited the phosphorylation of cytoplasmic β-catenin, confirming Wnt/β-catenin pathway activation (Figure 4a ). Reduced β-catenin phosphorylation prevents its degradation, leading to cytoplasmic accumulation and translocation into the nucleus. As expected, LiCl increased EC dysfunction (Figures 2 and 3) , further confirming that simvastatin regulates the Wnt/β-catenin pathway; we propose that simvastatin exerts a protective effect by inhibiting the Wnt/β-catenin pathway via β-catenin phosphorylation (Figure 4 ), leading to its degradation and reduced nuclear translocation.
Cholesterol is one of the main components of lipid rafts, which are involved in numerous cellular and signal transduction processes since many receptors and signal transduction-related proteins are localized in or associated with them [28] . For example, transmembrane signal transduction via the LPS receptor (TLR4) and TGF-β receptors is associated with and dependent upon lipid rafts [29, 30] . LRP6 plays a vital role in mediating Wnt/β-catenin signal transduction, and its distribution in lipid rafts facilitates Wnt/β-catenin signaling [31] [32] [33] . Methyl-β-cyclodextrin can downregulate the expression of LRP6 and β-catenin by depleting cholesterol levels and disrupting the structure of lipid rafts. Furthermore, increased cholesterol levels increase clonogenic potential and upregulate the expression of LRP6 and β-catenin [34] . In this study, simvastatin was used to inhibit cholesterol biosynthesis. Figure 6 shows that intracellular cholesterol levels were decreased by simvastatin treatment; however, the expression and phosphorylation of LRP6 were not significantly affected (Figure 4b ). These results suggest that simvastatin did not affect signaling upstream of the Wnt/β-catenin pathway.
ER stress occurs when the morphology and function of the ER are altered as a result of endogenous or exogenous stimuli, and may lead to the accumulation of misfolded proteins in the ER. During ER stress, the expression of GRP78, CHOP, and ATF6 increases [21] . Recent studies have shown that the Wnt/β-catenin pathway can affect ER stress; in cancer cells, inhibition of the Wnt/β-catenin pathway induces ER stress, which then leads to apoptosis [35, 36] . Furthermore, Zhang et al. proposed that inhibiting the Wnt/β-catenin pathway and β-catenin degradation reverses the inhibition of ATF6 by LEF1, resulting in ATF6-induced ER stress in preadipocytes [37] . This pathway is negatively correlated with ER stress in preadipocytes; however, we observed contradictory results in HUVECs. Simvastatin blocked the activation of ER stress and the Wnt/β-catenin pathway while LiCl activated the pathway and increased the expression of ER stress-related proteins (ATF6, GRP78, and CHOP; Figure 4c ), indicating that the Wnt/β-catenin pathway is positively correlated with ER stress in HUVECs. Although these results contradict one another, the Wnt/β-catenin pathway is clearly an important regulator of ER stress. In this study, simvastatin did not block transmembrane signal transduction in the Wnt/β-catenin pathway as it did not alter the expression or phosphorylation of LRP6 (Figure 4b) , indicating that the Wnt/β-catenin pathway did not inhibit ER stress. Some studies believed that changes in ER lipid composition under cholesterol overload may disrupt ER membrane functions and cause an accumulation of misfolded and unfolded ER proteins, which can trigger ER stress [38] [39] [40] [41] . Therefore, we propose that simvastatin blocks ER stress by inhibiting HMG-COA reductase, thus reducing intracellular cholesterol accumulation in HUVECs (Figure 6 ).
To further investigate the mechanism underlying the inhibition of the Wnt/β-catenin pathway by simvastatin, HUVECs were treated with tunicamycin (an ER stress activator) or 4-PBA (an ER stress inhibitor). When ER stress was induced by tunicamycin, total β-catenin levels increased and phosphorylated β-catenin levels decreased. When ER stress was inhibited by 4-PBA, total β-catenin levels decreased and phosphorylated β-catenin levels increased ( Figure 5 ). Therefore, we concluded that simvastatin inhibited the Wnt/β-catenin pathway by inhibiting ER stress, since simvastatin did not affect the expression or phosphorylation of LRP6.
Altogether, our results show that simvastatin did not affect transmembrane signal transduction in the Wnt/β-catenin pathway, but inhibited ER stress by reducing intracellular cholesterol accumulation, which blocked intracellular signal transduction in the Wnt/β-catenin pathway and reduced endothelial dysfunction (Figure 7 ).
Conclusions
Simvastatin did not affect transmembrane signal transduction in the Wnt/β-catenin pathway, but inhibited ER stress by reducing intracellular cholesterol accumulation, which blocked intracellular signal transduction in the Wnt/β-catenin pathway and reduced endothelial dysfunction. The mechanism of simvastatin in alleviating endothelial dysfunction under oxidative stress. LRP6 is localized to the cell membrane, and it is phosphorylated after it accumulates in the lipid raft Figure 7 . The mechanism of simvastatin in alleviating endothelial dysfunction under oxidative stress. LRP6 is localized to the cell membrane, and it is phosphorylated after it accumulates in the lipid raft which contributes to activate intracellular signal transduction in the Wnt/β-catenin pathway and then induce ER stress and endothelial dysfunction. Simvastatin can block intracellular cholesterol synthesis, which depresses endoplasmic reticulum stress and endothelial dysfunction, but does not further affect the phosphorylation of LRP6 by affecting lipid rafts. Therefore, although, simvastatin does not affect transmembrane signal transduction in the Wnt/β-catenin pathway, but blocks intracellular signal transduction in the Wnt/β-catenin pathway by attenuating the ER stress.
Materials and Methods
Cell Culture and Treatment
HUVECs were purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and were cultured in DMEM containing penicillin (100 U/mL), streptomycin (0.1 mg/mL), and 10% fetal calf serum at 37 • C in an incubator containing 5% CO 2 . THP-1 cells (Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences) were cultured in RPMI-1640 and incubated under the same conditions as the HUVECs.
Grouping and Dosing
To determine the optimal simvastatin concentration, HUVECs were cultured in 6-well plates. When the cells reached 70% confluence they were treated with different doses of simvastatin (0, 0.1, 0.2, 0.4, or 0.8 µmol/L) for 24 h. The lactate dehydrogenase (LDH) level in the medium and β-catenin, Bax, and Bcl-2 protein levels were then quantified. To determine whether simvastatin had a protective effect on endothelial cells under oxidative stress and to identify the underlying mechanism, HUVECs were treated with either lithium chloride (LiCl), simvastatin, or both. HUVECs were divided into the following four groups: C, treated with H 2 O 2 ; Li, treated with LiCl + H 2 O 2 ; Sim, treated with simvastatin + H 2 O 2 ; and Li+Sim, treated with simvastatin + LiCl + H 2 O 2 . After cells reached 70% confluence, simvastatin (0.2 µmol/L) was added to the Sim and Li+Sim groups. Two hours later, LiCl (20 µmol/L) was added to the Li and Li+Sim groups. After 24 h, 500 µmol/L H 2 O 2 was added to the C, Li, Sim, and Li+Sim groups. Then after another 24 h, the cells were collected for further analysis. To investigate whether the Wnt/β-catenin pathway affected ER stress, HUVECs were treated with tunicamycin (10 µmol/L, Tun group) or 4-phenylbutyric acid (10 mmol/L, 4-PBA group). The protein expression of β-catenin, phospho-β-catenin, and the ER stress-related molecules, GRP78, ATF6, and CHOP, was measured.
Measurement of LDH Levels in the Medium and Intracellular SOD Activity and MDA Concentration
The LDH level in the culture medium and the intracellular SOD activity and MDA concentration can reflect EC dysfunction. After the HUVECs were treated as described above, the medium was collected from the six-well plate and its LDH level was measured using a commercially available kit. The cells from the six-well plate were digested with trypsin, collected, disrupted using ultrasound, and centrifuged at 10,000 rpm for 10 min at 4 • C. The SOD activity and MDA concentration of the resulting supernatant were measured using a commercially available kit according to the manufacturer's instructions.
Measurement of Adhesion Ability of HUVECs to THP-1 Cells
HUVECs were cultured in 24-well plates as described above. After incubation with H 2 O 2 for 24 h, THP-1 cells (1 × 10 5 cells/well) were added. After 2 h, the medium in each well was removed and unattached THP-1 cells were washed away with PBS. The number of THP-1 cells adhered to the HUVECs was counted using a microscope (magnification, ×20; Olympus IX71; Olympus Corporation, Tokyo, Japan).
Western Blotting Analysis
To measure protein expression levels, cells were lysed and total protein was collected. Samples were then boiled in protein loading buffer at 100 • C for 5 min. Total proteins were extracted from the cells, subjected to 8-12% SDS-PAGE, and transferred to polyvinyl fluoride microporous membranes. Membranes were blocked with 5% skim milk or 5% bovine serum albumin, dissolved in Tris-buffered saline/Tween 20 (TBST) for 1 h, and incubated at 4 • C overnight with primary antibodies (human apoptosis-associated proteins Bcl-2 and Bax; adhesion-associated proteins ICAM-1, VCAM-1 and MCP-1; Wnt/β-catenin pathway-associated proteins β-catenin, phosphorylated β-catenin, LRP6, and phosphorylated LRP6; key molecules of ER stress GRP78, ATF6, and CHOP; and GAPDH) at a 1:1000 dilution. Membranes were then washed three times with TBST and incubated with a secondary antibody for 1 h at room temperature. After washing three times, an enhanced chemiluminescent reagent was added to the membrane and the blot was visualized using an autoradiography system (Chemiluminescence Imaging System; version 5.1; Bio-Rad Laboratories, Inc., Hercules, CA, USA). Each set of experiments was performed three times.
Measurement of Cell Viability by MTT Assay
To determine the effect of simvastatin on the viability of HUVECs under oxidative stress, they were seeded onto 96-well plates at a density of 1 × 10 5 cells/well and cultured as described above. Next, 20 µL of MTT (5 mg/mL) was added to each well, the cells were incubated at 37 • C for 4 h, the medium was removed, and 200 µL of dimethyl sulfoxide was added to each well to dissolve the blue precipitate. The absorbance was measured at 490 nm using a microplate reader (Thermo Fisher Scientific, Inc., Waltham, MA, USA). A total of 6 wells were measured per group and the experiment was performed three times.
Filipin Staining
2.5 × 10 4 cells were cultured in the 24-well plate after the glass lips were added. When HUVECs reached 70% confluence in the 24-well plate, the four cell groups were treated with different drugs, as described above. The medium in each well was then removed and the cells were washed three times with PBS. After being fixed with 4% paraformaldehyde for 30 min, the cells were washed with PBS three more times, 1.5 mg/mL of glycine was added to each well, and the cells were incubated in the glycine solution for 10 min. Finally, 500 µL of Filipin (0.05 mg/mL Filipin in PBS) was added to each well, incubated for 2 h, then the fluorescence intensity of each group was observed using a fluorescence microscope (magnification, ×10; Olympus IX71). The experiment was performed three times [42] .
Statistical Analysis
The data were analyzed using the statistical software, SPSS 22.0 (IBM Corp., Armonk, NY, USA). Significant differences between the groups were determined using one-way analysis of variance. All results represent at least 3 independent experiments. Differences with p values < 0.05 were considered statistically significant.
Conclusions
Simvastatin did not affect transmembrane signal transduction in the Wnt/β-catenin pathway, but inhibited ER stress by reducing intracellular cholesterol accumulation, which blocked intracellular signal transduction in the Wnt/β-catenin pathway and reduced endothelial dysfunction.
